ClinicalTrials.gg

Prader-Willi Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 144 studies for Prader-Willi Syndrome across more than 10 countries. 23 are recruiting or about to start. 122 of them are mainly about Prader-Willi Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
81
Recruiting
16
Terminated
16
Status unknown
10
Withdrawn
8
Active, not recruiting
6

Phase

Phase 2
33
Phase 3
27
Phase 1
12
Phase 4
7

Where

United States
69
France
27
Canada
15
United Kingdom
12
Spain
11
Australia
8

Who develops what

Add Prader-Willi Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 5 with this as their studies’ main aim; 1 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Harmony Biosciences and Rhythm Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.BMB-101 · Bright Minds Biosciences Pty Ltd · Phase 2 main aimNCT07266324 A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. — primary endpoint: Change from Baseline in Hyperphagia Questionnaire for Clinical Trials scores over time in Prader-Willi Syndrome participants. · 16 enrolled
  • Apr 2027 est.pitolisant · Harmony Biosciences Holdings, Inc. · Phase 3 main aimNCT06366464 A Study of Pitolisant in Patients With Prader-Willi Syndrome — primary endpoint: Change in severity of EDS as measured by Patient-Reported Outcomes Measurement Information System Bank v1.0 - Sleep-Related Impairment (PROMIS-SRI) T-score · 134 enrolled
  • Jun 2027 est.CSTI-500 · ConSynance Therapeutics · Phase 2 main aimNCT07348601 A Study of CSTI-500 in Patients With Prader-Willi Syndrome — primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) · 12 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Prader-Willi Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 1 open

Coming up

9studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger. 11 (69%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
108 (50%)8 (50%)
1812 (75%)12 (75%)
3010 (63%)10 (63%)
4010 (63%)10 (63%)
5010 (63%)10 (63%)
657 (44%)7 (44%)
757 (44%)7 (44%)
857 (44%)7 (44%)

Across all 144 studies, recruiting or not: 74% stop at 75 or younger and 73% at 65; 76% take children; 1% are for women only and 1% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Prader-Willi Syndrome studies take

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 219 mo15–27 · 11 studies——
Interventional, no phase29 mo14–43 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 144. Browse all 144 → or search them.